Dhru Deb, PhD

10

221

Dhru Deb, PhD@CancerSciArtist·24 Eki

The most inspiring thing about my job is to partner with amazing researchers and advocates who volunteer their stellar experience to help #lungcancer patients! @BrendonStilesMD @ODonnellLab_K @ipreeshagul & @ZieglerColleen thank you for your help with LCRF.org/symposium

English

2

14

521

Dhru Deb, PhD@CancerSciArtist·22 Eki

Final round selection is happening to invest $2.5 million towards curing oncogene-driven lung cancer! Truly transformative research proposals and stellar discussion by scientific and research advocate reviewers! #LCSM #lungcancer #oncogene @lcrf_org @IASLC

New funding opportunity: IASLC-LCRF Team Science Research Grant on Advancing Therapies Towards Curing Oncogenic-Driven Lung Cancers, a $2.5 million, four-year award: LCRF.org/24tsan View the RFP and apply at LCRF.org/funding.

English

6

304

Dhru Deb, PhD@CancerSciArtist·19 Eki

What's the biggest unmet need for you? We want to hear from YOU. If you are a #lungcancer patient, caregiver, family member, physician, clinician, researcher, join us and share your voice at the @lcrf_org annual symposium on Nov 4! The esteemed panel will address unmet needs!

#SaveTheDate for LCRF's 2024 Scientific Symposium: Monday, Nov. 4, 3-6pm ET. Our experts will lead a discussion on Lung Cancer: Addressing Unmet Needs. Registration is open for this virtual event: LCRF.org/symposium #LungCancer #LCAM

Queens, NY 🇺🇸 English

Stephen V Liu, MD@StephenVLiu

3

11

685

Dhru Deb, PhD retweetledi

Jill Feldman@jillfeldman4·14 Eki

Very interesting finding for people with #EGFR #lungcancer that transforms to #SCLC! It appears that DLL3 was not present before transformation, but most patients showed DLL3 expression after it. Currently, there isn't a good standard treatment, but further studies are needed to understand and determine if treatments targeting DLL3, such as tarlatamab, could be an option for patients after transformation. #LCSM @EGFRResisters

Retrospective report in European Journal of Cancer on #EGFR mutant NSCLC transformed to #SCLC. Post transformation, 93% were DLL3 positive. Are BiTEs like tarlatamab viable options here? No clear current standard (chemo, chemo + TKI, chemo + IO). ejcancer.com/article/S0959-…

English

EGFR Resisters Research Summit@EGFRSummit

7

31

4K

Dhru Deb, PhD@CancerSciArtist·1 Eki

If your #LUNGCANCER research is related to EGFR, consider this summit! It's a great opportunity to meet other researchers and advocates to tackle this oncogene together! @jillfeldman4 @EGFRResisters

🚨⏳ FINAL CALL to submit your abstract for 2024 #EGFRSummit DEADLINE TODAY ➡ce.ceconcepts.com/EGFR24 @jillfeldman4 @ZPiotrowskaMD @StephenVLiu @HelenaYu923 @maryjofidlerMD @christine_lovly @egfrresisters @CEC_onc #LCSM #EGFR

Queens, NY 🇺🇸 English

82

Dhru Deb, PhD@CancerSciArtist·28 Eyl

@innovsophie Thanks, Sophie. I would love to know more about your advocacy work! I manage the research advocate program at LCRF and it's fascinating how advocacy helps to shape the unmet needs in lung cancer that research can address

English

24

Dhru Deb, PhD@CancerSciArtist·28 Eyl

Our symposium for lung cancer patients & caregivers, discussing where research addresses unmet needs for immunotherapy, palliative care, telemedicine, KRAS, advocacy, small-cell and brain metastasis. Register & get ready with your questions for this amazing panel on Nov 4. #lcsm

#SaveTheDate for LCRF's 2024 Scientific Symposium: Monday, Nov. 4, 3-6pm ET. Our experts will lead a discussion on Lung Cancer: Addressing Unmet Needs. Registration is open for this virtual event: LCRF.org/symposium #LungCancer #LCAM

English

4

14

607

Dhru Deb, PhD@CancerSciArtist·25 Eyl

@BalazsHalmosMD @lcrf_org Thank you Dr. Halmos for attending the event!

English

2

51

Balazs Halmos@BalazsHalmosMD·25 Eyl

Living Breathing Science+ a large dose of compassion in the search for the C word- Cure in the treatment of lung cancer What a celebration of the amazing career of Dr. Kris elevating our field of thor onc from irrelevance to the poster child of onc w cure as a palpable reality!

English

2

3

27

1.6K

Dhru Deb, PhD@CancerSciArtist·25 Eyl

Drs. Politi & Vaishnavi at @lcrf_org 's evening on innovation!

Manhattan, NY 🇺🇸 English

10

396

Dhru Deb, PhD@CancerSciArtist·25 Eyl

@lcrf_org Evening of Innovation Gala begins tonight! Raising fund to support #lungcancer research! #lcsm #metropolitanclub

Manhattan, NY 🇺🇸 English

2

59

Dhru Deb, PhD@CancerSciArtist·23 Eyl

We are in round 2 of the selection process and what amazing proposals here! Great team science towards finding cure for oncogene-driven #lungcaner @lcrf_org @IASLC #lcsm

New funding opportunity: IASLC-LCRF Team Science Research Grant on Advancing Therapies Towards Curing Oncogenic-Driven Lung Cancers, a $2.5 million, four-year award: LCRF.org/24tsan View the RFP and apply at LCRF.org/funding.

Queens, NY 🇺🇸 English

3

17

1.8K

Dhru Deb, PhD@CancerSciArtist·17 Eyl

Celebrating the launch of research grants on lung cancer HER2 alterations by @lcrf_org and @BayerPharma with @alitimumab and team! We did ideation to launch in 4 months! Excited to see some ground breaking research that incorporates patients' voice from the get-go!

LCRF is pleased to announce its collaboration with Bayer Pharmaceuticals to fund two research grants focused on innovative strategies to advance understanding and management of #LungCancer with HER2 mutations and/or other HER2 alterations. Find out more at LCRF.org/her2research

Queens, NY 🇺🇸 English

8

535

Dhru Deb, PhD retweetledi

JessicaJLinMD@JessicaJLinMD·10 Eyl

Pleased to share an updated efficacy, safety, and biomarker analysis of Larotrectinib in TRK fusion+ NSCLC, presented at the #WCLC24 today [1/6]

English

3

8

43

4.2K

Dhru Deb, PhD@CancerSciArtist·11 Eyl

Last day of #WCLC24 : learnt so much, hugged so many friends, got inspired by the research and advocacy from all over the world and felt very hopeful that we all are in this together! #lcsm #lungcancer

San Diego, CA 🇺🇸 English

1

11

389

Dhru Deb, PhD@CancerSciArtist·9 Eyl

Huge thanks to all members of the @lcrf_org family, partners and collaborators for making our scientific board meeting such a blast last evening! Special thanks to Kelsey Hecker @IASLC in helping with our in person meeting during #wclc24 Excited for the new directions in research

San Diego, CA 🇺🇸 English

11

466

Dhru Deb, PhD@CancerSciArtist·6 Eyl

As a scientist by training for me this was a crash course on patient advocacy! So exciting to see advocates from all over the world!

LCRF's Dhru Deb @CancerSciArtist with fellow patient advocates at today's Global Lung Cancer Coalition @globalungcancer meeting! #patientvoices #lungcancerresearch

San Diego, CA 🇺🇸 English

9

373

Dhru Deb, PhD@CancerSciArtist·6 Eyl

Warm up to #WCLC24 began yesterday for me by meeting with ~40 #lungcancer #patientadvocates from around the world at the GLCC meeting reception! Looking forward to seeing all the members of @lcrf_org family over the next couple of days!

San Diego, CA 🇺🇸 English

8

367

Dhru Deb, PhD@CancerSciArtist·5 Eyl

"Liberating HER": Excited to see this partnership going from ideation at #aacr24 to announcement at #wclc24 in 5 months! My "research advocate" friends, this is such a promising step for #HER2 #lungcancer patients! #lcsm

LCRF is pleased to announce its collaboration with Bayer Pharmaceuticals to fund two research grants focused on innovative strategies to advance understanding and management of #LungCancer with HER2 mutations and/or other HER2 alterations. Find out more at LCRF.org/her2research

English

1

5

556

Dhru Deb, PhD@CancerSciArtist·5 Eyl

@Yvonne_Diaz_ @lcrf_org Thank you, Yvonne! Let's also celebrate the central role research advocates like yourself play in helping to formulate and select the best and the brightest research for lung cancer!

Queens, NY 🇺🇸 English

0

2

26

Yvonne Diaz@Yvonne_Diaz_·5 Eyl

@lcrf_org Fantastic to see this collaboration and focus on research to support those with HER2 lung cancers 👏👏

Kensington, London 🇬🇧 English

0

6

116

Lung Cancer Research Foundation@lcrf_org·5 Eyl

LCRF is pleased to announce its collaboration with Bayer Pharmaceuticals to fund two research grants focused on innovative strategies to advance understanding and management of #LungCancer with HER2 mutations and/or other HER2 alterations. Find out more at LCRF.org/her2research

Lung Cancer Research Foundation tweet media

English